📰 Poster Section News
Page 4 - Poster Section News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Poster Section. Real-time updates on events, politics, business and more.
April 19, 2023
Preliminary data of anchored canine IL-12 (cANK-101) in dogs with malignant melanoma demonstrates tolerable safety and early signs of biologic activity. Human ANK-101 is an IL-12-based anchored immunotherapy with IND submission planned for late 2023BOSTON--(BUSINESS WIRE)--Ankyra Therapeutics, a pre-clinical-stage o...
April 18, 2023
/PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that the company will present data showcasing the deep learning algorithm...
April 18, 2023
Data demonstrate higher internalization in cMET positive (cMET+) tumor cells and broader, more potent efficacy, including a greater than 3-fold increase in efficacy in mouse models of non-small cell lung cancer (NSCLC), as compared to other cMET-targeting ADCsData establish preclinical proof of concept for MYTX-011...
April 17, 2023
Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from ...
April 17, 2023
/PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, today announced its presentation of two posters at the...
April 14, 2023
Bio-Thera Solutions, Ltd. , a commercial-stage pharmaceutical company, today announced the company will present one poster concerning Phase 1 clinical results for BAT1006 at the 2023 American... | April 14, 2023
April 14, 2023
/PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel...
April 13, 2023
Abstract 473 highlights the dose dependent reduction of menin target genes in ex vivo chronic lymphocytic leukemia patient samples treated with BMF-219, an investigational covalent inhibitor. BMF-219... | April 13, 2023
April 12, 2023
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biomunex Pharmaceuticals, a French biopharmaceutical company focused on the development of immunotherapies based on the discovery and development of bi- and multi-specific antibodies for the treatment of cancer, announced today that it will participate in and present new sc...
April 12, 2023
Biomunex Pharmaceuticals, a French biopharmaceutical company focused on the development of immunotherapies based on the discovery and development of bi- and multi-specific antibodies for the treatment